Second-Generation Antipsychotic Medications and Risk of Pneumonia in Schizophrenia
Kuo et al.
Schizophr Bull 2012;0:sbr202v1-sbr202.
ABSTRACT
| FULL TEXT
Clozapine Use in Schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) Studies from 2001 to 2009
Xiang et al.
Aust N Z J Psychiatry 2011;45:968-975.
ABSTRACT
| FULL TEXT
Are all antipsychotic drugs the same?
Leucht and Davis
Br. J. Psychiatry 2011;199:269-271.
ABSTRACT
| FULL TEXT
Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
Suzuki et al.
Br. J. Psychiatry 2011;199:275-280.
ABSTRACT
| FULL TEXT
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial
Girgis et al.
Br. J. Psychiatry 2011;199:281-288.
ABSTRACT
| FULL TEXT
Atypical Antipsychotics Cause an Acute Increase in Cutaneous Hand Blood Flow in Patients with Schizophrenia and Schizoaffective Disorder
Blessing et al.
Aust N Z J Psychiatry 2011;45:646-653.
ABSTRACT
| FULL TEXT
Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards
Tungaraza et al.
The Psychiatrist 2011;35:288-292.
ABSTRACT
| FULL TEXT
Underuse of clozapine in treatment-resistant schizophrenia
Mistry and Osborn
Adv. Psychiatr. Treat. 2011;17:250-255.
ABSTRACT
| FULL TEXT
Using clozapine in clinical practice
Mortimer
Adv. Psychiatr. Treat. 2011;17:256-265.
ABSTRACT
| FULL TEXT
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Barnes and the Schizophrenia Consensus Group of the British A
J Psychopharmacol 2011;25:567-620.
ABSTRACT
| FULL TEXT
Current Treatment Strategies for Clozapine-Induced Sialorrhea
Bird et al.
The Annals of Pharmacotherapy 2011;45:667-675.
ABSTRACT
| FULL TEXT
The Ironies of Clozapine
Nasti
Aust N Z J Psychiatry 2011;45:345-346.
FULL TEXT
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
Stone
Therapeutic Advances in Psychopharmacology 2011;1:5-18.
ABSTRACT
Melperone in treatment-refractory schizophrenia: a case series
Whiskey et al.
Therapeutic Advances in Psychopharmacology 2011;1:19-23.
ABSTRACT
Functional SNPs in Genes Encoding the 5-HT2A Receptor Modify the Affinity and Potency of Several Atypical Antipsychotic Drugs
Davies et al.
Biol Res Nurs 2011;13:55-60.
ABSTRACT
Clozapine and blood dyscrasia
Latif et al.
The Psychiatrist 2011;35:27-29.
ABSTRACT
| FULL TEXT
Psychiatrists' attitude towards and knowledge of clozapine treatment
Nielsen et al.
J Psychopharmacol 2010;24:965-971.
ABSTRACT
Review: The biological basis of antipsychotic response in schizophrenia
Stone et al.
J Psychopharmacol 2010;24:953-964.
ABSTRACT
Time to 'Get Real': Preliminary Insights into the Long-Term Management of Schizophrenia
Malhi et al.
Australas Psychiatry 2010;18:115-119.
ABSTRACT
| FULL TEXT
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias and Remington
Schizophr Bull 2010;36:359-369.
ABSTRACT
| FULL TEXT
Mental illness that is difficult to classify: a case study
Igoumenou et al.
BMJ Case Reports 2009;2009:bcr0420091736-bcr0420091736.
ABSTRACT
| FULL TEXT
Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia
Attard and Gaughran
Evid. Based Ment. Health 2009;12:112-112.
FULL TEXT
Outcomes for schizophrenia patients with clozapine treatment: how good does it get?
Wheeler et al.
J Psychopharmacol 2009;23:957-965.
ABSTRACT
Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia
Liu et al.
J Psychopharmacol 2009;23:937-943.
ABSTRACT
Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Parks et al.
Schizophr Bull 2009;35:931-936.
ABSTRACT
| FULL TEXT
Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial
Zink et al.
J Psychopharmacol 2009;23:305-314.
ABSTRACT
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi and Folsom
Schizophr Bull 2009;35:528-548.
ABSTRACT
| FULL TEXT
What We Know: Findings That Every Theory of Schizophrenia Should Explain
MacDonald and Schulz
Schizophr Bull 2009;35:493-508.
ABSTRACT
| FULL TEXT
Clozapine: more than 900 mg/day may be needed
MacCall et al.
J Psychopharmacol 2009;23:206-210.
ABSTRACT
Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
Barbui et al.
Schizophr Bull 2009;35:458-468.
ABSTRACT
| FULL TEXT
The Role of Pharmacogenetics in Treating Central Nervous System Disorders
Patnaik et al.
Exp Biol Med 2008;233:1504-1509.
ABSTRACT
| FULL TEXT
Evaluating the association between clozapine and venous thromboembolism
Paciullo
Am J Health Syst Pharm 2008;65:1825-1829.
ABSTRACT
| FULL TEXT
Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives
Lang et al.
J Psychopharmacol 2008;22:576-580.
ABSTRACT
Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle
Halene and Siegel
J. Pharmacol. Exp. Ther. 2008;326:230-239.
ABSTRACT
| FULL TEXT
Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand
Wheeler
The Annals of Pharmacotherapy 2008;42:852-860.
ABSTRACT
| FULL TEXT
Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations
Morgan et al.
The Psychiatrist 2008;32:174-177.
ABSTRACT
| FULL TEXT
Increased cortical inhibition in persons with schizophrenia treated with clozapine
Daskalakis et al.
J Psychopharmacol 2008;22:203-209.
ABSTRACT
Unanswered Questions in Schizophrenia Clinical Trials
Kane and Leucht
Schizophr Bull 2008;34:302-309.
FULL TEXT
CATIE and CUtLASS: can we handle the truth?
Lewis and Lieberman
Br. J. Psychiatry 2008;192:161-163.
ABSTRACT
| FULL TEXT
Clozapine Use in a Forensic Population in a New South Wales Prison Hospital
Martin et al.
Aust N Z J Psychiatry 2008;42:141-146.
ABSTRACT
| FULL TEXT
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Kumra et al.
Schizophr Bull 2008;34:60-71.
ABSTRACT
| FULL TEXT
How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Owens
Adv. Psychiatr. Treat. 2008;14:17-28.
ABSTRACT
| FULL TEXT
References and further reading
Castle and Buckley
OPL Schizophrenia 2008;1:med-9780199549610-chapter-med-9780199549610-chapter.
FULL TEXT
Clozapine-induced leukopenia successfully treated with lithium
Kutscher et al.
Am J Health Syst Pharm 2007;64:2027-2031.
ABSTRACT
| FULL TEXT
Research into putative biological mechanisms of mental disorders has been of no value to clinical psychiatry
KINGDON and YOUNG
Br. J. Psychiatry 2007;191:285-290.
FULL TEXT
Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response
Hwang et al.
J Psychopharmacol 2007;21:718-727.
ABSTRACT
Acute Myocarditis Associated with Clozapine
Varambally and Howpage
Australas Psychiatry 2007;15:343-346.
ABSTRACT
| FULL TEXT
Antipsychotic Medication Use in the Elderly Patient
Malone et al.
Journal of Pharmacy Practice 2007;20:318-326.
ABSTRACT
Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence
Chan and Sweeting
J Psychopharmacol 2007;21:657-664.
ABSTRACT
Symptom rating scales and outcome in schizophrenia
Mortimer
Br. J. Psychiatry 2007;191:s7-s14.
ABSTRACT
| FULL TEXT
Measurement of long-term outcomes in observational and randomised controlled trials
Hodgson et al.
Br. J. Psychiatry 2007;191:s78-s84.
ABSTRACT
| FULL TEXT
The Neuropharmacology of Psychosis
Tamminga and Davis
Schizophr Bull 2007;33:937-946.
ABSTRACT
| FULL TEXT
Persistent Negative Symptoms in Schizophrenia: An Overview
Buchanan
Schizophr Bull 2007;33:1013-1022.
ABSTRACT
| FULL TEXT
Integrating Jungian and Self-Psychological Perspectives Within Cognitive-Behavior Therapy for a Young Man With a Fixed Religious Delusion
Silverstein
Clinical Case Studies 2007;6:263-276.
ABSTRACT
Is clozapine aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Karunakaran et al.
J Psychopharmacol 2007;21:453-456.
ABSTRACT
Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review
Stone et al.
J Psychopharmacol 2007;21:440-452.
ABSTRACT
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large
J Psychopharmacol 2007;21:283-301.
ABSTRACT
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Noel
Am J Health Syst Pharm 2007;64:863-876.
FULL TEXT
The history of clozapine and its emergence in the US market: a review and analysis.
Crilly
History of Psychiatry 2007;18:39-60.
ABSTRACT
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
Kim et al.
Proc. Natl. Acad. Sci. USA 2007;104:3456-3459.
ABSTRACT
| FULL TEXT
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses
Turner and Stewart
J Psychopharmacol 2006;20:20-37.
ABSTRACT
Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia
Lewis et al.
Schizophr Bull 2006;32:715-723.
ABSTRACT
| FULL TEXT
Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Lieberman
Arch Gen Psychiatry 2006;63:1069-1072.
FULL TEXT
Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning.
Friedman
Neurology 2006;67:564-566.
ABSTRACT
| FULL TEXT
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison.
Shaw et al.
Arch Gen Psychiatry 2006;63:721-730.
ABSTRACT
| FULL TEXT
Are older antipsychotic drugs obsolete?
Ganguli and Strassnig
BMJ 2006;332:1346-1347.
FULL TEXT
An Industry Perspective on the NIMH Consensus Statement on Negative Symptoms
Alphs
Schizophr Bull 2006;32:225-230.
ABSTRACT
| FULL TEXT
Selecting Patients for Long-acting Novel Antipsychotic Therapy
Lambert
Australas Psychiatry 2006;14:38-42.
ABSTRACT
| FULL TEXT
Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist
Burstein et al.
J. Pharmacol. Exp. Ther. 2005;315:1278-1287.
ABSTRACT
| FULL TEXT
Developing Drugs for Cognitive Impairment in Schizophrenia
Breier
Schizophr Bull 2005;31:816-822.
ABSTRACT
| FULL TEXT
Clinical implications of Brief Psychiatric Rating Scale scores
LEUCHT et al.
Br. J. Psychiatry 2005;187:366-371.
ABSTRACT
| FULL TEXT
Clozapine, agranulocytosis, and benign ethnic neutropenia
Rajagopal
Postgrad. Med. J. 2005;81:545-546.
FULL TEXT
Long-Term Course of Adolescent Schizophrenia
Fleischhaker et al.
Schizophr Bull 2005;31:769-780.
ABSTRACT
| FULL TEXT
Modern antipsychotic drugs: a critical overview
Gardner et al.
CMAJ 2005;172:1703-1711.
ABSTRACT
| FULL TEXT
Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication: Randomised controlled trial
VALMAGGIA et al.
Br. J. Psychiatry 2005;186:324-330.
ABSTRACT
| FULL TEXT
Management of clozapine-resistant schizophrenia
Kerwin and Bolonna
Adv. Psychiatr. Treat. 2005;11:101-106.
ABSTRACT
| FULL TEXT
Psychiatry in the future: What has research done for my practice?
Holloway
The Psychiatrist 2004;28:277-278.
FULL TEXT
Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
Durif et al.
Neurology 2004;62:381-388.
ABSTRACT
| FULL TEXT
Schizophrenia
Nadeem et al.
Evid. Based Ment. Health 2004;7:2-3.
FULL TEXT
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity
Sur et al.
Proc. Natl. Acad. Sci. USA 2003;100:13674-13679.
ABSTRACT
| FULL TEXT
Use of Antipsychotic Medications in Australian States and Territories Between July 1995 and December 2001
Mond et al.
Australas Psychiatry 2003;11:267-272.
ABSTRACT
| FULL TEXT
Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination
MONCRIEFF
Br. J. Psychiatry 2003;183:161-166.
ABSTRACT
| FULL TEXT
Origins of Early Intervention in First-Episode Psychosis
Sanbrook and Harris
Australas Psychiatry 2003;11:215-219.
ABSTRACT
| FULL TEXT
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis et al.
Arch Gen Psychiatry 2003;60:553-564.
ABSTRACT
| FULL TEXT
Aripiprazole: Does Partial Dopaminergic Agonism Translate into Clinical Benefits?
Crismon et al.
The Annals of Pharmacotherapy 2003;37:738-740.
FULL TEXT
Use of Antipsychotic Medications in Australia Between July 1995 and December 2001
Mond et al.
Aust N Z J Psychiatry 2003;37:55-61.
ABSTRACT
| FULL TEXT
A Five Year Follow-Up Study of the Use of Clozapine in Community Practice
Drew et al.
Aust N Z J Psychiatry 2002;36:780-786.
ABSTRACT
| FULL TEXT
Clozapine initiation in the community
O'Brien and Firn
The Psychiatrist 2002;26:339-341.
ABSTRACT
| FULL TEXT
Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis
GOOD et al.
Br. J. Psychiatry 2002;181:s45-s49.
ABSTRACT
| FULL TEXT
A 23-Year-Old Man With Schizophrenia
Goff
JAMA 2002;287:3249-3257.
FULL TEXT
